Description
Setipiprant research compound
Setipiprant is an oral DP2 (CRTH2) receptor antagonist that blocks prostaglandin D2 signalling.
Product details
| Compound | Setipiprant (ACT-129968) |
|---|---|
| Class | DP2 (CRTH2) receptor antagonist |
| Form | Powder |
| Strength | 5g |
| Labelling | Compound name and strength on every container |
Select your format and strength from the options above.
What research has examined
- PGD2/DP2 signalling.
- Allergic inflammation research.
- Hair follicle research: PGD2 hypothesis.
Research interest does not establish a proven effect in humans.
Regulatory status
This compound is not an approved medicine. It is supplied only as a research chemical for laboratory use.
Storage and handling
Store sealed in a cool, dry place away from light and moisture. Use clean, dry tools when weighing.
Independent literature: search PubMed for published studies.
Related research products
Cordyceps Sinensis · N-Acetyl-Cysteine Ethyl Ester · ISRIB · All research powders
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.